As a kid, studying was supposed to be a luxury funded by parents. But the reality? Everything was filtered through 'will this help me pass exams?' Never got to enjoy learning itself.
What I actually enjoyed: the dopamine hit of memorizing test-optimized info faster than others and winning the competition. Not the joy of learning.
Sometimes I'd stumble on something genuinely interesting, but then immediately think 'this won't boost my score, can't waste time on it' and drop it.
Now as an adult with financial stability, the real luxury is learning purely out of curiosity—not for career advancement, not for survival, just because you want to know.
You might eventually reach the same knowledge that exams demand, but the path you take to get there? That's the rich, luxurious part.
Anthropic dropped a report basically confirming what we all suspected: zero privacy when dealing with big AI corps. Your data is their training set.
Meanwhile, API middleman services are printing money with a genius scam: rebrand the product, mark it up, then flip user data on the side for extra revenue. Double-dipping at its finest.
Kimi (月之暗面) hit a major leak involving sensitive info. Regulators are coming for them hard, and their IPO timeline just got pushed back indefinitely.
In M&A news: Semianalysis acquired Citrini. Consolidation in the AI analysis/research space continues.
Apple banned early iPhone Duo reviewers from showing the device with screen off—likely hiding visible crease issues. This is a red flag for build quality. If the fold mechanism leaves a noticeable mark when powered down, it suggests either the hinge tech isn't as refined as Samsung's latest folds, or the OLED panel itself can't handle repeated stress without deformation. Apple's historically tight review embargoes usually mean they're managing optics around a known hardware compromise. Worth waiting for teardowns to see if this is a material science limitation or just a first-gen trade-off.
Semaglutide extended lifespan in aged mice by 12%. The critical question: is this longevity gain from the drug itself or just caloric restriction?
Semaglutide suppresses appetite, so mice were essentially under passive calorie restriction. The team compared semaglutide-treated mice against a 24% calorie-restricted control group.
Results: Both groups showed similar improvements in locomotion, muscle mass, and endurance. But semaglutide mice had more distributed feeding patterns and outperformed the calorie-restricted group in exploratory behavior, spatial memory, and glucose regulation.
Conclusion: GLP-1 receptor activation delivers benefits beyond simple caloric deficit. There's a mechanistic layer here that pure restriction doesn't capture.
This might signal AI+BIO hitting an inflection point where computational drug design is surfacing compounds with multi-pathway effects that weren't predictable from reductionist models alone.
Suno v6 feels like a deliberate trade-off: cleaner output, but possibly at the cost of some creative chaos that made earlier versions interesting. The big win here is instruction-following precision—it's way more controllable now, which matters if you're trying to nail specific vocal characteristics or style constraints.
What's technically impressive: the model preserves source vocal timbre much better than v5. If you feed it reference audio, it actually respects the voice profile instead of blending it into generic AI slop. This suggests improved disentanglement in the latent space—likely separating vocal identity from style/content more cleanly.
For anyone building voice workflows or experimenting with AI music generation, v6's increased steerability is a huge upgrade. You can now treat it more like a precision tool than a random idea generator.